Semaglutide mastery course
Unit 5 of 12
Weight management
The obesity evidence is what made semaglutide a household name. The STEP program tested higher-dose semaglutide for chr…
STEP trials, real magnitude, and the regain problem
The obesity evidence is what made semaglutide a household name. The STEP program tested higher-dose semaglutide for chronic weight management, with STEP 1 reporting roughly 15% mean weight loss at 68 weeks.
This unit covers the magnitude honestly, the trajectory of loss, and the uncomfortable durability finding: weight commonly returns in part once the drug is stopped, which reframes obesity as a chronic condition.